The division—formerly called Scimed—has already added hundreds of jobs in Maple Grove since last summer, most of them related to its new Taxus drug-coated stent, which was developed in Maple Grove. The new stent is expected to get regulatory approval to be sold in the US in a matter of days or weeks. Securities analysts think Boston Scientific will capture a major share of a market that could reach $5 billion in annual sales in the next year or two.
NOT FOR REPRINT
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.
